Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract

• US 10,639,319 B2
• Filed: 08/13/2012
• Issued: 05/05/2020
• Est. Priority Date: 08/29/2011
• Status: Active Grant

• Current Assignee: Abbott Laboratories
• Original Assignee: Abbott Laboratories
• Inventors: Davis, Steven R., Chow, Jomay
• Primary Examiner(s): Nguyen, Nghi V
• Application Number:
  US14/238,822
• Publication Number:
  US 20140335065A1
• Time in Patent Office: 2,822 Days
• Field of Search: 424 93, 514 54
• CPC Class Codes: A23L 33/21 Addition of substantially indigestible substances, e.g. dietary fibres
• CPC Class Codes: A23L 33/28 Substances of animal origin, e.g. gelatin or collagen
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, children, and adults for preventing injury and/or improving the healing of the gastrointestinal tract. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.

Claims

1. A method of stimulating the healing response of an individual'"'"'s gastrointestinal tract, the method comprising:

administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′

-sialyllactose, 6′

-sialyllactose, 2′

-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual having an injured gastrointestinal tract, wherein the individual'"'"'s gastrointestinal tract is injured as a result of at least one of radiation therapy, chemotherapy, enteric infection, inflammatory bowel disease, colitis, and bowel obstruction;

wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and

wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ

.

2. The method of claim 1 wherein the nutritional composition comprises 2′

-Fucosyllactose.

3. The method of claim 1 wherein the nutritional composition further comprises at least one probiotic.

4. The method of claim 1, wherein the nutritional composition is selected from the group consisting of a human milk fortifier, an infant formula, a pediatric formula, a follow-on formula, and an adult nutritional composition.

5. The method of claim 4, wherein the nutritional composition is an infant formula.

6. The method of claim 4, wherein the nutritional composition comprises 2′

-Fucosyllactose and at least one probiotic.

7. A method of reducing the incidence of intestinal mucosa injury, the method comprising:

administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′

-sialyllactose, 6′

-sialyllactose, 2′

-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual susceptible to an intestinal mucosa injury;

wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and

wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ

.

8. The method of claim 7 wherein the nutritional composition comprises 2′

-Fucosyllactose.

9. The method of claim 7 wherein the nutritional composition further comprises at least one probiotic.

10. The method of claim 7 wherein the nutritional composition is selected from the group consisting of a human milk fortifier, an infant formula, a pediatric formula, a follow on formula, and an adult nutritional composition.

11. A method of stimulating the expression of one or more mucin-associated proteins in an individual'"'"'s gastrointestinal tract, the method comprising:

administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′

-sialyllactose, 6′

-sialyllactose, 2′

-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual in need thereof

wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and

wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ

.

12. The method of claim 11 wherein the nutritional composition comprises 2′

-Fucosyllactose.

13. The method of claim 11 wherein the nutritional composition further comprises at least one probiotic.

14. A method of reducing the incidence of inflammation in an individual'"'"'s gastrointestinal tract, the method comprising:

administering a nutritional composition comprising a human milk oligosaccharide selected from the group consisting of 3′

-sialyllactose, 6′

-sialyllactose, 2′

-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose, disialyllacto-N-tetraose, and combinations thereof to an individual susceptible to inflammation of the gastrointestinal tract;

wherein the nutritional composition comprises 0.01 mg to less than 2 mg of the human milk oligosaccharide per mL of the composition, and

wherein administration of the nutritional composition stimulates at least one mucin-associated protein selected from TFF3, MUC2, and RELMβ

.